Second auto-SCT for treatment of relapsed multiple myeloma

Research output: Contribution to journalReview articlepeer-review

45 Scopus citations


High-dose therapy and auto-SCT remain integral in the initial treatment of multiple myeloma (MM), and are increasingly being applied for management of relapsed disease. We examined the outcomes in 98 patients undergoing salvage auto-SCT (auto-SCT2) for relapsed MM after receiving an initial transplant (auto-SCT1) between 1994 and 2009. The median age at auto-SCT2 was 60 years (range: 35-74). The median time between auto-SCT1 and auto-SCT2 was 46 months (range: 10-130). Treatment-related mortality was seen in 4%. The median PFS from auto-SCT2 was 10.3 (95% confidence interval (CI): 7-14) months and the median OS from auto-SCT2 was 33 months (95% CI: 28-51). In a multivariable analysis, shorter time to progression (TTP) after auto-SCT1, not achieving a CR after auto-SCT2, higher number of treatment regimens before auto-SCT2 and a higher plasma cell labeling index at auto-SCT2 predicted for shorter PFS. However, only a shorter TTP after auto-SCT1 predicted for a shorter OS post auto-SCT2. Hence, auto-SCT2 is an effective and feasible therapeutic option for MM patients relapsing after other treatments, especially in patients who had a TTP of at least 12 months after their auto-SCT1.

Original languageEnglish (US)
Pages (from-to)568-573
Number of pages6
JournalBone Marrow Transplantation
Issue number4
StatePublished - Apr 2013


  • auto-SCT
  • multiple myeloma
  • salvage therapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Second auto-SCT for treatment of relapsed multiple myeloma'. Together they form a unique fingerprint.

Cite this